Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | FUBP1 | Q96AE4 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22536652 | 0.90 | ALDH1A1 (0.51) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL14288350 | 0.84 | ALDH1A1 (0.55) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL14412548 | 0.76 | ALDH1A1 (0.56) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL12620551 | 0.76 | ALDH1A1 (0.55) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL13719338 | 0.75 | ALDH1A1 (0.52) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL13471700 | 0.75 | ALDH1A1 (0.60) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL5674583 | 0.73 | ALDH1A1 (0.58) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL4246156 | 0.72 | ALDH1A1 (0.51) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL12568259 | 0.72 | ALDH1A1 (0.56) | ALDH1A1GAAL3MBTL1PTGES2POLB | |
| SCHEMBL6209112 | 0.72 | ALDH1A1 (0.43) | ALDH1A1GAAL3MBTL1PTGES2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | ALDH1A1 529/4885GAA 862/4885L3MBTL1 375/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | ALDH1A1 2295/4885GAA 925/4885L3MBTL1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.